已收盤 06-18 16:00:00 美东时间
-0.150
-5.45%
今日重点评级关注:HC Wainwright & Co.:维持Elicio Therapeutics"买入"评级,目标价从17美元升至23美元;Leerink Partners:维持SAB Biotherapeutics"跑赢大市"评级,目标价从7美元升至12美元
06-16 11:34
LUCID CAPITAL MARKETS analyst Elemer Piros initiates coverage on Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy rating and announces Price Target of $6.
06-16 01:18
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(1.48) per share which beat the analyst consensus estimate of $(2.73) by 45.79 percent. This is a 82.59 percent increase over losses of $(8.50) per share
05-09 06:15
Adial Pharmaceuticals completes AD04 demo batch, validating process transfer and enabling Phase 3 production and FDA IND updates.
04-22 21:21
Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.
03-24 21:13
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(11.48) per share which missed the analyst consensus estimate of $(0.09) by 12655.56 percent. This is a 206.13 percent decrease over losses of $(3.75) per
03-06 21:07
Adial Pharma signs Europe deal with Molteni for AD04, eyeing up to $60 million in milestones and royalties.
03-03 21:02
Shares of Super Micro Computer Inc (NASDAQ:SMCI) rose sharply in pre-market tra...
02-04 17:33
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,
02-04 05:23
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,
01-14 22:03